Please assess the completion status of the following clinical trial:

Trial Title: Benfotiamine in Alzheimer's Disease: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years of age or older~* Clinical diagnosis of AMCI by the Peterson criteria or probable AD dementia according to the National Institute of Neurological Disorders and stroke and the Alzheimer's Disease related Disorders Association (NINCDS/ADRDA)~* MMSE score \> or equal to 21~* CDR score \> or equal to 0.5 and \< or equal to1~* Cornell Scale for Depression in Dementia(CSDD) score \<10.~* Ambulatory or ambulatory with aide~* Have a caregiver willing to accompany the patient to each visit, accept responsibility for supervising treatment and provided input to clinical outcome assessments~* Reside at home~* Speak English~* Amyloid positive PET-scan~* If they are on AD medications they must be stable on AD medications for at least three months prior to baseline~* Subjects ore willing/able to provide informed consent.~Exclusion Criteria:~* Patients with significant neurological disorder other than AD including hypoxia, stroke, traumatic brain injury~* A current psychiatric disorder according the DSM-IV diagnosis of major depression unless successfully treated on a stable dose of an antidepressant for at least 4 weeks and continues on stable dose throughout the study~* Any other DSM-IV Axis l diagnosis including other primary neurodegenerative dementia schizophrenia or bipolar depression~* A current diagnosis of uncontrolled diabetes mellitus (glucose values \> 200 mg/ml).~* Patients with uncontrolled diabetes will be excluded because high glucose will alter the FDG-PET studies. The clinic that does PET (Columbia University Medical Center) excludes patients if glucose values exceed 200 mg/ml.~* A current diagnosis of active, uncontrolled seizure disorder~* A current diagnosis of probable or possible vascular dementia according to NINDS-AIREN~* An investigational drug during the previous 4 weeks~* A current diagnosis of severe unstable cardiovascular disease~* A current diagnosis of acute severe, or unstable asthmatic condition (e.g., severe chronic obstructive pulmonary disease (COPD),~* A current diagnosis of cardiac, renal or hepatic disease~* History of alcoholism, current or within past 5 years~* A disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, severe language difficulty)~* A1C less than or equal to 8~* Current diagnosis of cancer/active treatments

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Benfotiamine (Type: EXPERIMENTAL): The patients in this arm will be treated with benfotiamine
- Placebo (Type: PLACEBO_COMPARATOR): The patients in this arm will be treated with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).